|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 95 No. 11 (June 1), 2000:
pp. 3310-3322
Improved outcome in childhood acute lymphoblastic leukemia despite
reduced use of anthracyclines and cranial radiotherapy: results of
trial ALL-BFM 90
Martin Schrappe,
Alfred Reiter,
Wolf-Dieter Ludwig,
Jochen Harbott,
Martin Zimmermann,
Wolfgang Hiddemann,
Charlotte Niemeyer,
Günter Henze,
Andreas Feldges,
Felix Zintl,
Bernhard Kornhuber,
Jörg Ritter,
Karl Welte,
Helmut Gadner, and
Hansjörg Riehm for the German-Austrian-Swiss ALL-BFM Study Group
From the Department of Pediatric Hematology and Oncology,
Medizinische Hochschule Hannover, Federal Republic of Germany (FRG);
Department of Hematology, Oncology and Tumor Immunology, Charité,
Campus Berlin-Buch, Humboldt University, Berlin, FRG; Oncogenetic
Laboratory, University Children's Hospital, Gießen, FRG; Department
of Hematology and Oncology, University Göttingen; Germany;
Department of Pediatrics, University Freiburg, FRG; Ostschweizerisches
Kinderspital, St Gallen, Switzerland; Department of Pediatric
Hematology and Oncology, Charité, Humboldt University, Berlin,
FRG; Department of Pediatric Hematology and Oncology, University Jena,
FRG; Department of Pediatric Hematology and Oncology, University
Frankfurt, FRG; Department of Pediatric Hematology and Oncology,
University Münster, FRG; and St Anna Kinderspital, Wien, Austria.
A complete list of the members of the German-Austrian-Swiss ALL-BFM
Study Group appears at the end of this article.
Trial ALL-BFM 90 was designed to improve outcome in patients with
childhood acute lymphoblastic leukemia (ALL) by using a reduced
treatment regimen. Patients were stratified into a standard-risk group (SRG), a medium-risk group (MRG), both defined by adequate early
treatment response; and a high-risk group (HRG), defined by inadequate
response to the cytoreductive prednisone prephase, induction failure,
or Philadelphia-chromosome-positive ALL. Four treatment
modifications were evaluated: dose intensification in induction by a more rapid drug sequence; administration
of L-asparaginase during consolidation therapy in the
MRG (randomized); enforced consolidation by rotational elements in
the HRG; and reduction in the dose of anthracyclines and use of only
12-Gy preventive cranial radiotherapy in the MRG and HRG, with the aim
of avoiding toxicity. Among all 2178 patients ( 18 years of age),
the 6-year event-free survival (EFS) rate (± SE) was
78% ± 1%, with a median observation time of 4.8 years. EFS was
85% ± 2% in the SRG (n = 636) and 82% ± 1% in the
MRG (n = 1299). L-asparaginase did not improve outcome
in the MRG: the event-free interval was 83% ± 2% with
L-asparaginase (n = 528) and 81% ± 2% without it
(n = 557). Because there were more systemic relapses in the HRG
(n = 243), EFS was 34% ± 3%, an outcome inferior to that in
the HRG in a previous trial, ALL-BFM 86, in which EFS was
47% ± 5% (P = .04). The rates of isolated central
nervous system relapse in the MRG and HRG were 0.8% and 1.6%,
respectively; thus, the 12-Gy preventive cranial radiotherapy regimen
apparently provided sufficient central nervous system prophylaxis.
The overall improvement over the results in ALL-BFM 86 (6-year EFS,
72%; P = .001) was based on fewer recurrences among
patients in the MRG with B-cell-precursor ALL, indicating an advantage
of more condensed induction therapy. In multivariate analysis,
inadequate in vivo response emerged as the strongest adverse prognostic variable.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
C.-H. Pui, D. Campana, D. Pei, W. P. Bowman, J. T. Sandlund, S. C. Kaste, R. C. Ribeiro, J. E. Rubnitz, S. C. Raimondi, M. Onciu, et al.
Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation
N. Engl. J. Med.,
June 25, 2009;
360(26):
2730 - 2741.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. French, W. Yang, C. Cheng, S. C. Raimondi, C. G. Mullighan, J. R. Downing, W. E. Evans, C.-H. Pui, and M. V. Relling
Acquired variation outweighs inherited variation in whole genome analysis of methotrexate polyglutamate accumulation in leukemia
Blood,
May 7, 2009;
113(19):
4512 - 4520.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Schrappe
Risk-adapted stratification and treatment of childhood acute lymphoblastic leukaemia
Radiat Prot Dosimetry,
December 1, 2008;
132(2):
130 - 133.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Teuffel, M. Stanulla, G. Cario, W. D. Ludwig, S. Rottgers, B. W. Schafer, M. Zimmermann, M. Schrappe, and F. K. Niggli
Anemia and survival in childhood acute lymphoblastic leukemia
Haematologica,
November 1, 2008;
93(11):
1652 - 1657.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Tucci and M. Arico
Treatment of pediatric acute lymphoblastic leukemia
Haematologica,
August 1, 2008;
93(8):
1124 - 1128.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Moricke, A. Reiter, M. Zimmermann, H. Gadner, M. Stanulla, M. Dordelmann, L. Loning, R. Beier, W.-D. Ludwig, R. Ratei, et al.
Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95
Blood,
May 1, 2008;
111(9):
4477 - 4489.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Oudot, M.-F. Auclerc, V. Levy, R. Porcher, C. Piguet, Y. Perel, V. Gandemer, M. Debre, C. Vermylen, B. Pautard, et al.
Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study
J. Clin. Oncol.,
March 20, 2008;
26(9):
1496 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Seibel, P. G. Steinherz, H. N. Sather, J. B. Nachman, C. DeLaat, L. J. Ettinger, D. R. Freyer, L. A. Mattano Jr, C. A. Hastings, C. M. Rubin, et al.
Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group
Blood,
March 1, 2008;
111(5):
2548 - 2555.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Pullarkat, M. L. Slovak, K. J. Kopecky, S. J. Forman, and F. R. Appelbaum
Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study
Blood,
March 1, 2008;
111(5):
2563 - 2572.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. H. Goldstone, S. M. Richards, H. M. Lazarus, M. S. Tallman, G. Buck, A. K. Fielding, A. K. Burnett, R. Chopra, P. H. Wiernik, L. Foroni, et al.
In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)
Blood,
February 15, 2008;
111(4):
1827 - 1833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Kawamata, S. Ogawa, M. Zimmermann, M. Kato, M. Sanada, K. Hemminki, G. Yamatomo, Y. Nannya, R. Koehler, T. Flohr, et al.
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray
Blood,
January 15, 2008;
111(2):
776 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. L. Seibel
Treatment of Acute Lymphoblastic Leukemia in Children and Adolescents: Peaks and Pitfalls
Hematology,
January 1, 2008;
2008(1):
374 - 380.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. V. Barry, S. E. Lipshultz, and S. E. Sallan
Anthracycline-induced Cardiotoxicity: Natural History, Risk Factors, and Prevention
ASCO Educational Book,
January 1, 2008;
2008(1):
448 - 453.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Felder-Puig, C. Scherzer, M. Baumgartner, M. Ortner, C. Aschenbrenner, C. Bieglmayer, T. Voigtlander, E. R. Panzer-Grumayer, W. J.E. Tissing, J. W. Koper, et al.
Glucocorticoids in the Treatment of Children with Acute Lymphoblastic Leukemia and Hodgkin's Disease: A Pilot Study on the Adverse Psychological Reactions and Possible Associations with Neurobiological, Endocrine, and Genetic Markers
Clin. Cancer Res.,
December 1, 2007;
13(23):
7093 - 7100.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Kager, T. Lion, A. Attarbaschi, M. Koenig, S. Strehl, O. A. Haas, M. N. Dworzak, M. Schrappe, H. Gadner, G. Mann, et al.
Incidence and outcome of TCF3-PBX1-positive acute lymphoblastic leukemia in Austrian children
Haematologica,
November 1, 2007;
92(11):
1561 - 1564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cario, S. Izraeli, A. Teichert, P. Rhein, J. Skokowa, A. Moricke, M. Zimmermann, A. Schrauder, L. Karawajew, W.-D. Ludwig, et al.
High Interleukin-15 Expression Characterizes Childhood Acute Lymphoblastic Leukemia With Involvement of the CNS
J. Clin. Oncol.,
October 20, 2007;
25(30):
4813 - 4820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Balduzzi, V. Conter, C. Uderzo, and M. G. Valsecchi
Transplantation in Childhood Very High Risk Acute Lymphoblastic Leukemia in First Complete Remission: Where Are We Now?
J. Clin. Oncol.,
June 20, 2007;
25(18):
2625 - 2626.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Svendsen, T. Weihkopf, P. Kaatsch, and J. Schuz
Exposure to Magnetic Fields and Survival after Diagnosis of Childhood Leukemia: A German Cohort Study
Cancer Epidemiol. Biomarkers Prev.,
June 1, 2007;
16(6):
1167 - 1171.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Hijiya, M. M. Hudson, S. Lensing, M. Zacher, M. Onciu, F. G. Behm, B. I. Razzouk, R. C. Ribeiro, J. E. Rubnitz, J. T. Sandlund, et al.
Cumulative Incidence of Secondary Neoplasms as a First Event After Childhood Acute Lymphoblastic Leukemia
JAMA,
March 21, 2007;
297(11):
1207 - 1215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Barry, D. J. DeAngelo, D. Neuberg, K. Stevenson, M. L. Loh, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, et al.
Favorable Outcome for Adolescents With Acute Lymphoblastic Leukemia Treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols
J. Clin. Oncol.,
March 1, 2007;
25(7):
813 - 819.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Moghrabi, D. E. Levy, B. Asselin, R. Barr, L. Clavell, C. Hurwitz, Y. Samson, M. Schorin, V. K. Dalton, S. E. Lipshultz, et al.
Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia
Blood,
February 1, 2007;
109(3):
896 - 904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-M. Ribera, J.-J. Ortega, A. Oriol, P. Bastida, C. Calvo, J.-M. Perez-Hurtado, M.-E. Gonzalez-Valentin, V. Martin-Reina, A. Molines, F. Ortega-Rivas, et al.
Comparison of Intensive Chemotherapy, Allogeneic, or Autologous Stem-Cell Transplantation As Postremission Treatment for Children With Very High Risk Acute Lymphoblastic Leukemia: PETHEMA ALL-93 Trial
J. Clin. Oncol.,
January 1, 2007;
25(1):
16 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Schrauder, A. Reiter, H. Gadner, D. Niethammer, T. Klingebiel, B. Kremens, C. Peters, W. Ebell, M. Zimmermann, F. Niggli, et al.
Superiority of Allogeneic Hematopoietic Stem-Cell Transplantation Compared With Chemotherapy Alone in High-Risk Childhood T-Cell Acute Lymphoblastic Leukemia: Results From ALL-BFM 90 and 95
J. Clin. Oncol.,
December 20, 2006;
24(36):
5742 - 5749.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. M. Saarinen-Pihkala, C. Heilmann, J. Winiarski, A. Glomstein, J. Abrahamsson, J. Arvidson, A. N. Bekassy, E. Forestier, G. Jonmundsson, H. Schroeder, et al.
Pathways Through Relapses and Deaths of Children With Acute Lymphoblastic Leukemia: Role of Allogeneic Stem-Cell Transplantation in Nordic Data
J. Clin. Oncol.,
December 20, 2006;
24(36):
5750 - 5762.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Matloub, S. Lindemulder, P. S. Gaynon, H. Sather, M. La, E. Broxson, R. Yanofsky, R. Hutchinson, N. A. Heerema, J. Nachman, et al.
Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group
Blood,
August 15, 2006;
108(4):
1165 - 1173.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Breit, M. Stanulla, T. Flohr, M. Schrappe, W.-D. Ludwig, G. Tolle, M. Happich, M. U. Muckenthaler, and A. E. Kulozik
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia
Blood,
August 15, 2006;
108(4):
1151 - 1157.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Efferth, J.-P. Gillet, A. Sauerbrey, F. Zintl, V. Bertholet, F. de Longueville, J. Remacle, and D. Steinbach
Expression profiling of ATP-binding cassette transporters in childhood T-cell acute lymphoblastic leukemia.
Mol. Cancer Ther.,
August 1, 2006;
5(8):
1986 - 1994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Eapen, E. Raetz, M.-J. Zhang, C. Muehlenbein, M. Devidas, T. Abshire, A. Billett, A. Homans, B. Camitta, W. L. Carroll, et al.
Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research
Blood,
June 15, 2006;
107(12):
4961 - 4967.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Attarbaschi, G. Mann, M. Konig, M. Steiner, S. Strehl, A. Schreiberhuber, B. Schneider, C. Meyer, R. Marschalek, A. Borkhardt, et al.
Mixed Lineage Leukemia-Rearranged Childhood Pro-B and CD10-Negative Pre-B Acute Lymphoblastic Leukemia Constitute a Distinct Clinical Entity.
Clin. Cancer Res.,
May 15, 2006;
12(10):
2988 - 2994.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M.S.M. Chan, D.J. Roebuck, M.-P. Yuen, C.-K. Li, and Y.-L. Chan
MR Imaging of the Brain in Patients Cured of Acute Lymphoblastic Leukemia--the Value of Gradient Echo Imaging
AJNR Am. J. Neuroradiol.,
March 1, 2006;
27(3):
548 - 552.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. O'Neil, J. Calvo, K. McKenna, V. Krishnamoorthy, J. C. Aster, C. H. Bassing, F. W. Alt, M. Kelliher, and A. T. Look
Activating Notch1 mutations in mouse models of T-ALL
Blood,
January 15, 2006;
107(2):
781 - 785.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui and W. E. Evans
Treatment of Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
January 12, 2006;
354(2):
166 - 178.
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui
Central Nervous System Disease in Acute Lymphoblastic Leukemia: Prophylaxis and Treatment
Hematology,
January 1, 2006;
2006(1):
142 - 146.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Rowe, G. Buck, A. K. Burnett, R. Chopra, P. H. Wiernik, S. M. Richards, H. M. Lazarus, I. M. Franklin, M. R. Litzow, N. Ciobanu, et al.
Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993
Blood,
December 1, 2005;
106(12):
3760 - 3767.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, D. Pei, J. T. Sandlund, D. Campana, R. C. Ribeiro, B. I. Razzouk, J. E. Rubnitz, S. C. Howard, N. Hijiya, S. Jeha, et al.
Risk of Adverse Events After Completion of Therapy for Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
November 1, 2005;
23(31):
7936 - 7941.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Pession, M. G. Valsecchi, G. Masera, W. A. Kamps, E. Magyarosy, C. Rizzari, E. R. van Wering, L. Lo Nigro, A. van der Does, F. Locatelli, et al.
Long-Term Results of a Randomized Trial on Extended Use of High Dose L-Asparaginase for Standard Risk Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
October 1, 2005;
23(28):
7161 - 7167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. C. Rocha, C. Cheng, W. Liu, S. Kishi, S. Das, E. H. Cook, J. T. Sandlund, J. Rubnitz, R. Ribeiro, D. Campana, et al.
Pharmacogenetics of outcome in children with acute lymphoblastic leukemia
Blood,
June 15, 2005;
105(12):
4752 - 4758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. R. Pine, C. Yin, Y. H. Matloub, H. E. Sabaawy, C. Sandoval, O. Levendoglu-Tugal, M. F. Ozkaynak, and S. Jayabose
Detection of Central Nervous System Leukemia in Children with Acute Lymphoblastic Leukemia by Real-Time Polymerase Chain Reaction
J. Mol. Diagn.,
February 1, 2005;
7(1):
127 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. DeAngelo
The Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia
Hematology,
January 1, 2005;
2005(1):
123 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, J. T. Sandlund, D. Pei, D. Campana, G. K. Rivera, R. C. Ribeiro, J. E. Rubnitz, B. I. Razzouk, S. C. Howard, M. M. Hudson, et al.
Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital
Blood,
November 1, 2004;
104(9):
2690 - 2696.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. V. Relling, and J. R. Downing
Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
April 8, 2004;
350(15):
1535 - 1548.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Styczynski and M. Wysocki
Is the In Vitro Drug Resistance Profile the Strongest Prognostic Factor in Childhood Acute Lymphoblastic Leukemia?
J. Clin. Oncol.,
March 1, 2004;
22(5):
963 - 964.
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. M. Holling, E. Schooten, A. W. Langerak, and P. J. van den Elsen
Regulation of MHC class II expression in human T-cell malignancies
Blood,
February 15, 2004;
103(4):
1438 - 1444.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, M. Schrappe, R. C. Ribeiro, and C. M. Niemeyer
Childhood and Adolescent Lymphoid and Myeloid Leukemia
Hematology,
January 1, 2004;
2004(1):
118 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Steinbach, S. Wittig, G. Cario, S. Viehmann, A. Mueller, B. Gruhn, R. Haefer, F. Zintl, and A. Sauerbrey
The multidrug resistance-associated protein 3 (MRP3) is associated with a poor outcome in childhood ALL and may account for the worse prognosis in male patients and T-cell immunophenotype
Blood,
December 15, 2003;
102(13):
4493 - 4498.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. E. Ross, X. Zhou, G. Song, S. A. Shurtleff, K. Girtman, W. K. Williams, H.-C. Liu, R. Mahfouz, S. C. Raimondi, N. Lenny, et al.
Classification of pediatric acute lymphoblastic leukemia by gene expression profiling
Blood,
October 15, 2003;
102(8):
2951 - 2959.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldberg, L. B. Silverman, D. E. Levy, V. K. Dalton, R. D. Gelber, L. Lehmann, H. J. Cohen, S. E. Sallan, and B. L. Asselin
Childhood T-Cell Acute Lymphoblastic Leukemia: The Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Experience
J. Clin. Oncol.,
October 1, 2003;
21(19):
3616 - 3622.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui, C. Cheng, W. Leung, S. N. Rai, G. K. Rivera, J. T. Sandlund, R. C. Ribeiro, M. V. Relling, L. E. Kun, W. E. Evans, et al.
Extended Follow-up of Long-Term Survivors of Childhood Acute Lymphoblastic Leukemia
N. Engl. J. Med.,
August 14, 2003;
349(7):
640 - 649.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. R. Kees, J. Ford, M. Watson, A. Murch, M. Ringner, R. L. Walker, and P. Meltzer
Gene Expression Profiles in a Panel of Childhood Leukemia Cell Lines Mirror Critical Features of the Disease
Mol. Cancer Ther.,
July 1, 2003;
2(7):
671 - 677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Konrad, M. Metzler, S. Panzer, I. Ostreicher, M. Peham, R. Repp, O. A. Haas, H. Gadner, and E. R. Panzer-Grumayer
Late relapses evolve from slow-responding subclones in t(12;21)-positive acute lymphoblastic leukemia: evidence for the persistence of a preleukemic clone
Blood,
May 1, 2003;
101(9):
3635 - 3640.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Boissel, M.-F. Auclerc, V. Lheritier, Y. Perel, X. Thomas, T. Leblanc, P. Rousselot, J.-M. Cayuela, J. Gabert, N. Fegueux, et al.
Should Adolescents With Acute Lymphoblastic Leukemia Be Treated as Old Children or Young Adults? Comparison of the French FRALLE-93 and LALA-94 Trials
J. Clin. Oncol.,
March 1, 2003;
21(5):
774 - 780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C.-H. Pui
Toward Optimal Central Nervous System-Directed Treatment in Childhood Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
January 15, 2003;
21(2):
179 - 181.
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Burger, M. Zimmermann, G. Mann, J. Kuhl, L. Loning, H. Riehm, A. Reiter, and M. Schrappe
Diagnostic Cerebrospinal Fluid Examination in Children With Acute Lymphoblastic Leukemia: Significance of Low Leukocyte Counts With Blasts or Traumatic Lumbar Puncture
J. Clin. Oncol.,
January 15, 2003;
21(2):
184 - 188.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ballerini, A. Blaise, M. Busson-Le Coniat, X. Y. Su, J. Zucman-Rossi, M. Adam, J. van den Akker, C. Perot, B. Pellegrino, J. Landman-Parker, et al.
HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis
Blood,
July 18, 2002;
100(3):
991 - 997.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Arico, M. G. Valsecchi, V. Conter, C. Rizzari, A. Pession, C. Messina, E. Barisone, V. Poggi, G. De Rossi, F. Locatelli, et al.
Improved outcome in high-risk childhood acute lymphoblastic leukemia defined by prednisone-poor response treated with double Berlin-Frankfurt-Muenster protocol II
Blood,
June 28, 2002;
100(2):
420 - 426.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hotfilder, S. Rottgers, A. Rosemann, H. Jurgens, J. Harbott, and J. Vormoor
Immature CD34+CD19- progenitor/stem cells in TEL/AML1-positive acute lymphoblastic leukemia are genetically and functionally normal
Blood,
June 28, 2002;
100(2):
640 - 646.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Korinthenberg, A. Schneider, and C. Niemeyer
Central Nervous System Prophylaxis With High-Dose Methotrexate Does Not Give Rise to Significant Electroencephalographic Changes in Children With Acute Lymphoblastic Leukemia
J Child Neurol,
June 1, 2002;
17(6):
409 - 412.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. J. Willemse, T. Seriu, K. Hettinger, E. d'Aniello, W. C. J. Hop, E. R. Panzer-Grumayer, A. Biondi, M. Schrappe, W. A. Kamps, G. Masera, et al.
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL
Blood,
May 29, 2002;
99(12):
4386 - 4393.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hoelzer, N. Gokbuget, W. Digel, T. Faak, M. Kneba, R. Reutzel, J. Romejko-Jarosinska, J. Zwolinski, and J. Walewski
Outcome of adult patients with T-lymphoblastic lymphoma treated according to protocols for acute lymphoblastic leukemia
Blood,
May 29, 2002;
99(12):
4379 - 4385.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Wuchter, V. Ruppert, M. Schrappe, B. Dorken, W.-D. Ludwig, and L. Karawajew
In vitro susceptibility to dexamethasone- and doxorubicin-induced apoptotic cell death in context of maturation stage, responsiveness to interleukin 7, and early cytoreduction in vivo in childhood T-cell acute lymphoblastic leukemia
Blood,
May 13, 2002;
99(11):
4109 - 4115.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Duval, S. Suciu, A. Ferster, X. Rialland, B. Nelken, P. Lutz, Y. Benoit, A. Robert, A.-M. Manel, E. Vilmer, et al.
Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer---Children's Leukemia Group phase 3 trial
Blood,
April 15, 2002;
99(8):
2734 - 2739.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. N. Dworzak, G. Froschl, D. Printz, G. Mann, U. Potschger, N. Muhlegger, G. Fritsch, and H. Gadner
Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia
Blood,
March 15, 2002;
99(6):
1952 - 1958.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski
Acute Lymphoblastic Leukemia
Hematology,
January 1, 2002;
2002(1):
162 - 192.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Ford, K. Fasching, E. R. Panzer-Grumayer, M. Koenig, O. A. Haas, and M. F. Greaves
Origins of "late" relapse in childhood acute lymphoblastic leukemia with TEL-AML1 fusion genes
Blood,
August 1, 2001;
98(3):
558 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Manabe, M. Tsuchida, R. Hanada, K. Ikuta, Y. Toyoda, Y. Okimoto, K. Ishimoto, H. Okawa, A. Ohara, T. Kaneko, et al.
Delay of the Diagnostic Lumbar Puncture and Intrathecal Chemotherapy in Children With Acute Lymphoblastic Leukemia Who Undergo Routine Corticosteroid Testing: Tokyo Children's Cancer Study Group Study L89-12
J. Clin. Oncol.,
July 1, 2001;
19(13):
3182 - 3187.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Strauss, J. T. Su, V. M. K. Dalton, R. D. Gelber, S. E. Sallan, and L. B. Silverman
Bony Morbidity in Children Treated for Acute Lymphoblastic Leukemia
J. Clin. Oncol.,
June 15, 2001;
19(12):
3066 - 3072.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Millot, S. Suciu, N. Philippe, Y. Benoit, F. Mazingue, A. Uyttebroeck, P. Lutz, F. Mechinaud, A. Robert, P. Boutard, et al.
Value of High-Dose Cytarabine During Interval Therapy of a Berlin-Frankfurt-Munster-Based Protocol in Increased-Risk Children With Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma: Results of the European Organization for Research and Treatment of Cancer 58881 Randomized Phase III Trial
J. Clin. Oncol.,
April 1, 2001;
19(7):
1935 - 1942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Rizzari, M.G. Valsecchi, M. Arico, V. Conter, A. Testi, E. Barisone, F. Casale, L. Lo Nigro, R. Rondelli, G. Basso, et al.
Effect of Protracted High-Dose L-Asparaginase Given as a Second Exposure in a Berlin-Frankfurt-Munster-Based Treatment: Results of the Randomized 9102 Intermediate-Risk Childhood Acute Lymphoblastic Leukemia Study--A Report From the Associazione Italiana Ematologia Oncologia Pediatrica
J. Clin. Oncol.,
March 1, 2001;
19(5):
1297 - 1303.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. B. Silverman, R. D. Gelber, V. K. Dalton, B. L. Asselin, R. D. Barr, L. A. Clavell, C. A. Hurwitz, A. Moghrabi, Y. Samson, M. A. Schorin, et al.
Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01
Blood,
March 1, 2001;
97(5):
1211 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Oki, Y. Kishi, M. Kami, O. Fruchter, M. G. Valsecchi, M. Schrappe, and C.-H. Pui
Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in Children
N. Engl. J. Med.,
October 5, 2000;
343(14):
1043 - 1044.
[Full Text]
|
|
|
|
|
